2.1 Cell lines and reagents
Human pancreatic cancer cells, PANC-1 (RRID:CVCL_0480), BxPC-3
(RRID:CVCL_0186), MIA PaCa-2 (RRID:CVCL_0428), CFPAC-1
(RRID:CVCL_1119), AsPC-1 (RRID:CVCL_0152), SW1990 (RRID:CVCL_1723),
Capan-2 (RRID:CVCL_0026), and HPAC (RRID:CVCL_3517), human prostate
cancer cells, PC-3 (RRID:CVCL_0035) and PC-3M (RRID:CVCL_9555), human
breast cancer cells, MDA-MB-231 (RRID:CVCL_0062), and other normal
cells, 293T (RRID:CVCL_0063), HaCaT (RRID:CVCL_0038), HAF
(RRID:CVCL_ZG36), and C2C12 (RRID:CVCL_0188), were purchased from Cell
Bank of the Chinese Academy of Sciences (Shanghai, China) or the
American Type Culture Collection (Manassas, VA, USA). PANC-1, HPAC,
HaCaT, HAF, and C2C12 cells were cultured in DMEM (Gibco) supplemented
with 10% FBS (Gibco) and 1% penicillin/streptomycin (Gibco). MIAPaCa-2
cells were maintained in DMEM supplemented with 10% FBS, 2.5% horse
serum (Gibco), 1% sodium pyruvate 100 mM solution (Invitrogen) and 1%
penicillin/streptomycin. AsPC-1, BxPC-3, Capan-2, and PC-3M cells were
cultured in RPMI 1640 (Gibco) supplemented with 10% FBS and 1%
penicillin/streptomycin. CFPAC-1 cells were grown in IMDM (Gibco)
supplemented with 10% FBS and 1% penicillin/streptomycin. SW1990 and
MDA-MB-231 cells were cultured in L-15 (Gibco) supplemented with 10%
FBS and 1% penicillin/streptomycin. PC-3 cells were maintained in
DMEM/F12 (Hyclone) medium supplemented with 10% FBS and 1%
penicillin/streptomycin. 293T cells were cultured in DMEM supplemented
with 10% FBS. All cell lines were maintained at 37 °C in a humidified
incubator containing 5% CO2. Trienomycin A (purity:
> 95% by HPLC) was isolated and purified by ourselves as
previously described (Tang et al., 2018). TA was dissolved in DMSO as a
10 mM stock solution and stored at -20 °C. Gemcitabine hydrochloride was
purchased from MedChemExpress (Shanghai, China). All STAT3
inhibitors (BP-1-102 and C188-9, dissolved in DMSO) were purchased from
Topscience (Shanghai, China). Recombinant human STAT3 (127-722 AA)
protein was kindly provided by Dr Zhengfang Yi (Institute of Biomedical
Sciences and School of Life Sciences, East China Normal University,
China).